Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2006 | 1 |
2012 | 1 |
2013 | 2 |
2016 | 1 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Lancet. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3.
Lancet. 2013.
PMID: 23830355
Clinical Trial.
[Visual evoked potential in leprosy patients].
de Andrade Neto JL, Cunha AP, Barreto RB, de Arantes TE, Santos LP.
de Andrade Neto JL, et al.
Arq Bras Oftalmol. 2006 Jul-Aug;69(4):575-8. doi: 10.1590/s0004-27492006000400022.
Arq Bras Oftalmol. 2006.
PMID: 17119734
Free article.
Portuguese.
Item in Clipboard
Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
Furtado J, Madruga JV, Bicudo EL, da Eira M, Lopes MI, Netto EM, Santini-Oliveira M, Leite OH, Machado AA, Tupinambas U, de Andrade Neto JL, Lima MP, Pedro Rde J, Miranda AF, Lewi DS, Santos BR, Portsmouth S, Wajsbrot DB, Cassoli LM.
Furtado J, et al. Among authors: de andrade neto jl.
AIDS Res Hum Retroviruses. 2013 Sep;29(9):1203-10. doi: 10.1089/AID.2012.0330. Epub 2013 Jun 25.
AIDS Res Hum Retroviruses. 2013.
PMID: 23731330
Clinical Trial.
Item in Clipboard
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Cooper DA, Cordery DV, Zajdenverg R, Ruxrungtham K, Arastéh K, Bergmann F, Neto JL, Scherer J, Chaves RL, Robinson P; study team.
Cooper DA, et al.
PLoS One. 2016 Jan 5;11(1):e0144917. doi: 10.1371/journal.pone.0144917. eCollection 2016.
PLoS One. 2016.
PMID: 26730818
Free PMC article.
Clinical Trial.
Item in Clipboard
Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials.
Caseiro MM, Nelson M, Diaz RS, Gathe J, de Andrade Neto JL, Slim J, Solano A, Netto EM, Mak C, Shen J, Greaves W, Dunkle LM, Vilchez RA, Zeinecker J.
Caseiro MM, et al. Among authors: de andrade neto jl.
J Infect. 2012 Oct;65(4):326-35. doi: 10.1016/j.jinf.2012.05.008. Epub 2012 May 24.
J Infect. 2012.
PMID: 22634184
Clinical Trial.
Item in Clipboard
Cite
Cite